We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
Read MoreHide Full Article
Key Takeaways
Beta Bionics partnered with Senseonics to integrate Eversense 365 with its iLet and future mint AID systems.
BBNX could broaden CGM choice by pairing automated insulin delivery with Eversense 365's one-year sensor.
BBNX is also advancing mint and its 3D Intelligence insulin dosing algorithm to expand its diabetes platform.
Beta Bionics, Inc. (BBNX - Free Report) recently announced a partnership with Senseonics (SENS - Free Report) to expand compatibility between its automated insulin delivery (AID) platform and Senseonics’ continuous glucose monitoring technology. The collaboration is expected to broaden device choice for people with diabetes and strengthen BBNX’s position in the growing automated diabetes management market.
The partnership could support BBNX’s long-term growth by expanding addressable user base and improving the competitiveness of its AID ecosystem. Greater CGM compatibility may also help drive adoption and enhance the company’s ability to differentiate its platform as diabetes care increasingly shifts toward connected and personalized solutions.
The integrated iLet and Eversense 365 system is expected to launch commercially in the fourth quarter of 2026. Following the launch, the iLet is expected to support Dexcom G6, Dexcom G7, Abbott’s FreeStyle Libre 3 Plus and Senseonics’ Eversense 365, giving users greater flexibility in choosing their preferred CGM technology. Beta Bionics expects this expanded compatibility to make the iLet compatible with more CGM manufacturers than any other AID system.
Likely Trend of BBNX Stock Following the News
Following the announcement on Sept. 22, shares of BBNX lost more than 8% in yesterday’s trading. Year to date, shares of the company have lost 32.6% compared with the industry’s 4.9% decline. However, the S&P 500 has risen 12.8% in the same timeframe.
From a long-term perspective, the partnership could benefit Beta Bionics by expanding the appeal of its automated insulin delivery ecosystem and potentially increasing adoption among people seeking greater flexibility in CGM options. Integration with Senseonics’ Eversense 365 could strengthen BBNX’s competitive positioning by supporting a broader device ecosystem and addressing demand for more convenient, long-duration glucose monitoring.
BBNX currently has a market capitalization of $967.7 million.
Beta Bionics’ iLet Bionic Pancreas is an AID system designed to simplify insulin management for people with diabetes. The system is built around a fully adaptive approach, using glucose readings from a compatible continuous glucose monitor to automatically determine and deliver insulin doses. Unlike conventional insulin pumps that require users to calculate and enter meal-related insulin doses, the iLet is designed to reduce the amount of manual decision-making involved in daily diabetes management. This positioning supports BBNX’s strategy of making insulin therapy more automated and easier to use.
The upcoming integration with Senseonics’ Eversense 365 is expected to further expand the range of CGM options supported by the iLet. This could enhance the system’s flexibility and allow more patients and healthcare providers to select a glucose-monitoring technology that aligns with their individual preferences and needs.
mint AID System: Expanding the Next-Generation Platform
Beta Bionics is also developing mint, its next-generation AID system, as part of its broader diabetes management platform. The company intends to integrate mint with Eversense 365 in the future, extending the benefits of expanded CGM compatibility beyond its existing iLet platform. The planned integration highlights BBNX’s efforts to build a broader technology ecosystem rather than relying on a single insulin delivery product.
Eversense 365: Long-Duration CGM Technology
Senseonics’ Eversense 365 is a continuous glucose monitoring system designed to provide glucose monitoring for up to one year with a single sensor. Its long-duration design differentiates it from conventional CGM systems that generally require more frequent sensor replacement. The technology is intended to provide continuous glucose data while reducing the burden associated with regular sensor changes, potentially making long-term glucose monitoring more convenient for patients.
Integrating Eversense 365 with BBNX’s AID platforms could create a more streamlined diabetes management solution by combining long-duration glucose sensing with automated insulin delivery. The collaboration may also broaden patient choice within BBNX’s ecosystem and strengthen the value proposition of its platforms. Importantly, the integration could help BBNX reach patients who prefer an extended-duration CGM while allowing the company to maintain a broader, more flexible AID offering.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global insulin patch pumps market size was estimated at USD 912.5 million in 2022 and is anticipated to expand at a CAGR of 10.9% from 2023 to 2030.
The high growth can primarily be attributed to factors such as technological advancements, the rising prevalence of diabetes and increasing awareness regarding advanced patch pumps.
Other News
Recently, BBNX secured FDA clearance for its Mint patch pump, marking a key milestone in expanding its automated insulin delivery portfolio. The company also unveiled its next-generation 3D Intelligence insulin dosing algorithm, which is currently under FDA review. The company outlined commercialization timelines for both innovations.
The clearance strengthens Beta Bionics' long-term growth story by opening the door to the fast-growing patch pump market and supporting broader pharmacy channel adoption.
BBNX’s Zacks Rank & Key Picks
Currently, BBNX has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) and Veracyte (VCYT - Free Report) .
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
View the Zacks #1 Rank List
Image: Bigstock
Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
Key Takeaways
Beta Bionics, Inc. (BBNX - Free Report) recently announced a partnership with Senseonics (SENS - Free Report) to expand compatibility between its automated insulin delivery (AID) platform and Senseonics’ continuous glucose monitoring technology. The collaboration is expected to broaden device choice for people with diabetes and strengthen BBNX’s position in the growing automated diabetes management market.
The partnership could support BBNX’s long-term growth by expanding addressable user base and improving the competitiveness of its AID ecosystem. Greater CGM compatibility may also help drive adoption and enhance the company’s ability to differentiate its platform as diabetes care increasingly shifts toward connected and personalized solutions.
The integrated iLet and Eversense 365 system is expected to launch commercially in the fourth quarter of 2026. Following the launch, the iLet is expected to support Dexcom G6, Dexcom G7, Abbott’s FreeStyle Libre 3 Plus and Senseonics’ Eversense 365, giving users greater flexibility in choosing their preferred CGM technology. Beta Bionics expects this expanded compatibility to make the iLet compatible with more CGM manufacturers than any other AID system.
Likely Trend of BBNX Stock Following the News
Following the announcement on Sept. 22, shares of BBNX lost more than 8% in yesterday’s trading. Year to date, shares of the company have lost 32.6% compared with the industry’s 4.9% decline. However, the S&P 500 has risen 12.8% in the same timeframe.
From a long-term perspective, the partnership could benefit Beta Bionics by expanding the appeal of its automated insulin delivery ecosystem and potentially increasing adoption among people seeking greater flexibility in CGM options. Integration with Senseonics’ Eversense 365 could strengthen BBNX’s competitive positioning by supporting a broader device ecosystem and addressing demand for more convenient, long-duration glucose monitoring.
BBNX currently has a market capitalization of $967.7 million.
Image Source: Zacks Investment Research
iLet Bionic Pancreas: Fully Automated Insulin Delivery
Beta Bionics’ iLet Bionic Pancreas is an AID system designed to simplify insulin management for people with diabetes. The system is built around a fully adaptive approach, using glucose readings from a compatible continuous glucose monitor to automatically determine and deliver insulin doses. Unlike conventional insulin pumps that require users to calculate and enter meal-related insulin doses, the iLet is designed to reduce the amount of manual decision-making involved in daily diabetes management. This positioning supports BBNX’s strategy of making insulin therapy more automated and easier to use.
The upcoming integration with Senseonics’ Eversense 365 is expected to further expand the range of CGM options supported by the iLet. This could enhance the system’s flexibility and allow more patients and healthcare providers to select a glucose-monitoring technology that aligns with their individual preferences and needs.
mint AID System: Expanding the Next-Generation Platform
Beta Bionics is also developing mint, its next-generation AID system, as part of its broader diabetes management platform. The company intends to integrate mint with Eversense 365 in the future, extending the benefits of expanded CGM compatibility beyond its existing iLet platform. The planned integration highlights BBNX’s efforts to build a broader technology ecosystem rather than relying on a single insulin delivery product.
Eversense 365: Long-Duration CGM Technology
Senseonics’ Eversense 365 is a continuous glucose monitoring system designed to provide glucose monitoring for up to one year with a single sensor. Its long-duration design differentiates it from conventional CGM systems that generally require more frequent sensor replacement. The technology is intended to provide continuous glucose data while reducing the burden associated with regular sensor changes, potentially making long-term glucose monitoring more convenient for patients.
Integrating Eversense 365 with BBNX’s AID platforms could create a more streamlined diabetes management solution by combining long-duration glucose sensing with automated insulin delivery. The collaboration may also broaden patient choice within BBNX’s ecosystem and strengthen the value proposition of its platforms. Importantly, the integration could help BBNX reach patients who prefer an extended-duration CGM while allowing the company to maintain a broader, more flexible AID offering.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global insulin patch pumps market size was estimated at USD 912.5 million in 2022 and is anticipated to expand at a CAGR of 10.9% from 2023 to 2030.
The high growth can primarily be attributed to factors such as technological advancements, the rising prevalence of diabetes and increasing awareness regarding advanced patch pumps.
Other News
Recently, BBNX secured FDA clearance for its Mint patch pump, marking a key milestone in expanding its automated insulin delivery portfolio. The company also unveiled its next-generation 3D Intelligence insulin dosing algorithm, which is currently under FDA review. The company outlined commercialization timelines for both innovations.
The clearance strengthens Beta Bionics' long-term growth story by opening the door to the fast-growing patch pump market and supporting broader pharmacy channel adoption.
BBNX’s Zacks Rank & Key Picks
Currently, BBNX has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) and Veracyte (VCYT - Free Report) .
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.